Skip to main content
Download PDF

Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations

BMC Gastroenterology volume 23, Article number: 365 (2023) Cite this article

Abstract

Background and Aim

Whether alcohol intake is associated with Helicobacter pylori (H. pylori) eradication failure remains controversial, and this meta-analysis was aimed at investigating the effect of alcohol on the risk of H. pylori eradication failure.

Methods

Relevant studies were systematically screened for and retrieved from PubMed and Web of Science (updated to January 2022), and relevant references were manually reviewed. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Subgroup, publication bias, and sensitivity analyses were also conducted.

Results

A total of 40 studies were included in the meta-analysis. No significant association was found between alcohol consumption and the risk of H. pylori eradication failure (OR = 1.09, 95% CI, 0.94–1.26). However, in subgroup analyses stratified by region, a positive association was found in Asian patients (OR = 1.23, 95% CI, 1.03–1.47). In Asian patients, alcohol consumption was associated with the risk of H. pylori eradication failure when the duration of therapy was > 7 days (OR = 1.17, 95% CI, 1.10–1.25), when the treatment regimen included nitroimidazoles (OR = 1.16, 95% CI, 1.09–1.24), and when patients were treated with bismuth-containing quadruple therapy (OR = 1.17, 95% CI, 1.10–1.25). Alcohol intake > 40 g/day was associated with H. pylori eradication failure (OR = 3.17, 95% CI, 1.56–6.41). Moreover, in Asian patients who were administered a vonoprazan (VPZ)-based therapy regimen, alcohol consumption had no effect on H. pylori eradication rates (OR = 1.73, 95% CI, 0.98–3.05).

Conclusion

Our meta-analysis clearly showed that a higher daily alcohol intake was associated with a higher risk of H. pylori eradication failure in Asian populations. Moreover, a VPZ-based treatment regimen can prevent this effect.

Peer Review reports

Introduction

Helicobacter pylori (H. pylori) infection is among the most prevalent infections in the world and affects approximately half of the population in Asia [1]. H. pylori can cause chronic gastritis, peptic ulcers, stomach cancer, and other digestive system diseases. Treatment of H. pylori infection can effectively control the occurrence and development of these diseases [2, 3]. The ideal regimen for treating H. pylori infection should return eradication rates of more than 90%–95% and 80% in per-protocol and intention-to-treat analyses, respectively, and should be well tolerated with few adverse effects (< 5%) [4]. However, sequential, concomitant, and bismuth-containing therapies used for H. pylori infection in recent years have not achieved satisfactory eradication rates [5]. As the chances of successful eradication decrease with increasing number of follow-up eradication attempts, factors leading to eradication failure should be identified and avoided to the extent possible [6].

Some studies have examined the influence of several factors on H. pylori eradication. The most common factors showing significant correlation with H. pylori eradication were antibiotic resistance [7, 8], smoking [9], cytochrome P450 (CYP) 2C19 genotype [10], body mass index (BMI) [3, 11], and poor treatment adherence [1, 12]. However, the effect of alcohol on H. pylori eradication has been less explored with controversial findings. Alcohol consumption was reported to significantly lower the H. pylori eradication rate [11, 12], suggesting its role in the increased risk of H. pylori eradication failure. Conversely, some studies have reported no association between alcohol consumption and the risk of H. pylori eradication failure [13,14,15]. Meanwhile, vonoprazan (VPZ), a novel potassium-competitive acid blocker (P-CAB), has been recently approved in Japan for H. pylori eradication [16]. Studies have shown that alcohol consumption does not affect the eradication rate of VPZ-based treatment regimens [2, 16, 17]. Therefore, a meta-analysis was conducted to clarify these discrepancies and investigate the association between alcohol consumption and the risk of H. pylori eradication failure.

Methods

This meta-analysis was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) guidelines [18]. The research problem was based on the PICO model: P [population]: Studies that recruited patients with H. pylori infection as participants; I [intervention or exposure]: alcohol consumption; C [comparison agent]: comparison between the alcohol group and the control group; and O [result]: H. pylori eradication.

Search strategy

A literature search was conducted on PubMed and Web of Science for all relevant literature published before January 2022 using the keywords (Helicobacter pylori eradication OR H. pylori eradication) AND (alcohol OR drinking). Some relevant studies were included on the basis of a manual review of references as well.

Inclusion criteria

In our meta-analysis, we included (1) studies exploring the effect of different levels of alcohol exposure (high vs. low; any vs. none) on H. pylori eradication; (2) studies with data for odds ratios (ORs) available or those in which the number of eradication cases could be obtained according to the drinking category; (3) studies published in English; and (4) first-line or second-line treatment studies for H. pylori eradication. Notably, if there were multiple studies of the same study population, the study with the largest sample size was included.

Exclusion criteria

We excluded (1) case reports, meeting abstracts, and commentaries; (2) studies with incomplete data; and (3) studies that were duplication or continuation of previous studies.

Data extraction

Two researchers (J.Y. and Y-M.L.) separately extracted information from all eligible articles and cross-checked each other’s findings. Any inconsistencies in results were resolved by a third senior investigator (X–Y.W.) until a consensus was reached. The following information was extracted for each study: first author, year of publication, country, study design, proportion of patients with peptic ulcers, number of participants, eradication regimens, treatment duration, method for assessing H. pylori eradication, interval for assessing H. pylori eradication after the therapy, and alcohol consumption. In addition, the quality of each included study was assessed independently by the two researchers using the Newcastle–Ottawa Scale (NOS) on the basis of three broad domains of selection, comparability, and exposure/outcome. Each study was scored on a scale of 0 to 9.

Statistical analysis

The association between alcohol consumption and the risk of H. pylori eradication failure was calculated using ORs and 95% confidence intervals (CIs). The reported OR and 95% CI were used when available and calculated when not available. Heterogeneity between studies was assessed by the Q test and I2 test. I2 ≤ 50% and P > 0.05 suggested no statistical heterogeneity, and in this case, the fixed-effects model was selected for data analysis; otherwise, the random-effects model was applied. Subgroup analysis was performed to explore the source of heterogeneity. Sensitivity analysis was performed to ensure the stability of meta-analysis results. Funnel plots were used for visual evaluation of publication bias; Egger's and Begg's tests were used for statistical assessment of publication bias. A P value of < 0.05 was considered statistically significant. All statistical analyses were performed using Stata software version 15.1 (Stata Corp LLC 4905 Lake Way Drive, College Station, TX 77845 USA).

Results

Study identification and selection

Figure 1 shows the details of literature retrieval. First, using the abovementioned keywords, 244 and 208 studies were obtained from PubMed and Web of Science, respectively. From among these studies, 114 studies were excluded because of duplication. Then, the titles and abstracts of the remaining 338 publications were reviewed, and 286 studies that did not meet the inclusion criteria were excluded. Then, the full text of the remaining 52 studies was evaluated, and 9 studies were included through manual retrieval of their references. From among these 61 studies, 21 studies were excluded because 11 studies did not contain sufficient data and 10 studies were not published in English. Finally, 40 studies were included in the final analysis.

Fig. 1
figure 1

Flow chart of study selection

Full size image

Study characteristics

Table 1 shows the characteristics of the 40 studies [1,2,3, 7, 8, 11,12,13,14,15,16,17, 19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46] selected. Among these studies, 24 studies [1,2,3, 7, 11,12,13, 16, 17, 22, 30, 32, 34,35,36,37,38,39,40,41, 43,44,45,46] were conducted in Asia and 16 outside Asia. Seven studies [15, 23, 26, 30,31,32, 37] included all patients with peptic ulcers as subjects. Among the studies conducted in Asia, only seven studies [16, 32, 36, 37, 43,44,45] had data on alcohol intake. Regarding the antibiotic agent(s) administered, clarithromycin was administered in 17 studies, and nitroimidazoles were administered in 3 studies [11, 32, 46]. A VPZ-based therapy regimen was followed in five studies [2, 3, 16, 17, 46]. The NOS results revealed that the average quality score was 6.2 (range, 5–8), indicating that the methodological quality of these studies was generally good.

Table 1 Characteristics of included studies
Full size table

Association between alcohol consumption and the risk of H. pylori eradication failure

Finally, 40 studies reporting the association between alcohol consumption and H. pylori eradication were analyzed. Owing to the significant heterogeneity among these studies (I2 = 47.9%, P-heterogeneity < 0.001), a random-effects model was applied. The risk of H. pylori eradication failure was not higher in drinkers than in non-drinkers (OR = 1.09, 95% CI, 0.94–1.26) (Fig. 2). To assess the effect of each individual study on the pooled effect size, sensitivity tests were performed by excluding one study at a time. Withdrawal of any study did not significantly alter the results. The pooled OR ranged from 0.94 to 1.26, confirming the robustness of the results. Neither visual assessment using the funnel plot (Fig. 3a) nor statistical assessment with Begg’s test (P = 0.401) or Egger’s test (P = 0.805) revealed any publication bias.

Fig. 2
figure 2

A forest plot of the association between alcohol and H. pylori eradication. Subgroup analysis was based on the region

Full size image
Fig. 3
figure 3

Funnel plots of publication bias (a: All studies included, b: Asian studies). Each round dot represents one study; Begg’s test or Egger’s test also showed no evidence of publication bias in both A and B subfigures

Full size image

Association between alcohol consumption and the risk of H. pylori eradication failure in Asia

Herein, 24 Asian studies reported on the effect of alcohol consumption on H. pylori eradication. There was significant heterogeneity among these studies (I2 = 41.5%, P-heterogeneity = 0.012), and a random-effects model was applied. The analysis results revealed alcohol as a risk factor for H. pylori eradication failure (OR = 1.23, 95% CI, 1.03–1.47) (Fig. 2). Next, sensitivity analysis was performed, and the pooled OR ranged from 1.03 to 1.47, confirming the robustness of the results. The funnel plot (Fig. 3b) was roughly symmetrical, and there was no publication bias on Begg’s test (P = 0.489) or Egger’s test (P = 0.455).

Subgroup analysis

The origin of heterogeneity was explored by subgroup analysis (Table 2). No significant differences were observed between the prospective studies (OR = 1.13, 95% CI, 0.92–1.38) and retrospective studies (OR = 1.05, 95% CI, 0.83–1.32), all of which indicated that alcohol consumption did not increase the risk of H. pylori eradication failure. When stratified by treatment options, a higher risk of eradication failure was not observed among drinkers undergoing first-line treatment (OR = 1.09, 95% CI, 0.94–1.26) or second-line treatment (OR = 1.25, 95% CI, 0.54–2.93). No significant differences were found between studies having all patients with peptic ulcer (OR = 0.83, 95% CI, 0.65–1.07) and those having a proportion of patients with peptic ulcer (OR = 1.19, 95% CI, 0.93–1.51), all of which indicated that alcohol consumption did not increase the risk of H. pylori eradication failure. Urea breath test (OR = 0.98, 95% CI, 0.82–1.16) and other methods (OR = 0.75, 95% CI, 0.51–1.09) used to evaluate H. pylori eradication were not associated with a higher risk of H. pylori eradication failure among drinkers.

Table 2 Subgroup analyses between alcohol consumption and the risk of H. pylori eradication failure
Full size table

Moreover, in Asian patients (Table 3), a treatment duration of > 7 days was associated with higher risk of H. pylori eradication failure (OR = 1.17, 95% CI, 1.10–1.25). Alcohol consumption was found to increase the risk of H. pylori eradication failure when the treatment regimen did not include clarithromycin (OR = 1.18, 95% CI, 1.10–1.26) or when the treatment regimen included nitroimidazoles (OR = 1.16, 95% CI, 1.09–1.24). Notably, alcohol consumption also decreased the eradication rate when bismuth-containing quadruple therapy (OR = 1.17, 95% CI, 1.10–1.25) was used to treat H. pylori infection in Asian patients; however, the H. pylori eradication efficacy of the VPZ-based therapy regimen (OR = 1.73, 95% CI, 0.98–3.05) remained unaffected by alcohol consumption. In addition, seven of the Asian studies provided information on the amount of alcohol intake. In these studies, increase in alcohol intake (> 40 g/day) was associated with a higher risk of H. pylori eradication failure (OR = 3.17, 95% CI, 1.56–6.41).

Table 3 Subgroup analyses between alcohol consumption and the risk of H. pylori eradication failure in Asia
Full size table

Discussion

Main findings

Our meta-analysis included 40 studies and assessed the potential association between alcohol consumption and the risk of H. pylori eradication failure. The overall pooled OR of drinkers versus non-drinkers was 1.09 (95% CI: 0.94–1.26), suggesting that alcohol consumption was not associated with and did not exacerbate the risk of H. pylori eradication failure. Stratified by the study region, our meta-analysis showed that increased alcohol consumption was associated with increased risk of H. pylori eradication failure in Asian studies. Compared to controls, individuals with alcohol consumption of over 40 g/day were more than three times likely to encounter H. pylori eradication failure. The association between alcohol consumption and the risk of H. pylori eradication failure is supported by several biological mechanisms. First, alcohol consumption activates gastric acid secretion, leading to a decrease in stomach pH, which promotes the breakdown of antibiotics and reduces their effectiveness [41]. In addition, ethanol can reportedly significantly affect the absorption rate of amoxicillin [47]. Second, alcohol has a strong induction effect on the liver enzyme CYP2C19 [48]. Meanwhile, for the CYP2C19 genotype, H. pylori eradication rates were reported to be lower in the rapid and intermediate metabolizer groups of proton pump inhibitors (PPIs) than in poor metabolizer groups [10]. Therefore, alcohol may affect the eradication rate by inducing CYP2C19. Moreover, alcohol can also alter the gastric microenvironment, thus affecting the stability of antibiotics and leading to a decrease in the eradication rate [44].

The discrepancy between the results of Asian and non-Asian studies may be explained by potential differences in their regional populations, such as genetic and physical differences. There are two major aldehyde dehydrogenase (ALDH) isoenzymes in the liver: cytoplasmic ALDH1 and mitochondrial ALDH2. The primary pathway by which ethanol is metabolized involves its degradation by alcohol dehydrogenase into acetaldehyde (an intermediate metabolite), which is then acted upon by ALDH and converted into acetic acid [49]. Previous studies have reported a widespread prevalence of ALDH deficiency in Oriental populations [50], and thus, it can be interpreted that Asians metabolize ethanol less efficiently than non-Asians. In addition, for the same BMI, Asians have a higher body fat percentage than Caucasians [51], and alcohol is not easily absorbed by adipose tissues because of its low fat solubility [52]. These factors also contribute to higher plasma alcohol concentrations in Asian populations than in non-Asian populations. These results suggest that alcohol consumption impacts Asian populations more strongly and therefore influences H. pylori eradication to a greater extent.

In Japan, the standard treatment for H. pylori eradication is a seven-day triple therapy, namely PPI or P-CAB combined with amoxicillin, clarithromycin, or metronidazole [53]. As a novel P-CAB, VPZ has been approved for H. pylori eradication in recent years [16]. Our findings showed that alcohol consumption did not detrimentally affect the efficacy of the VPZ-based therapy regimen, and although the reasons for this remain unknown, we can speculate that the strong inhibition of gastric acid by VPZ conceals the effect of alcohol on the H. pylori eradication rate [2]. Therefore, to further explore this phenomenon, prospective studies on the efficacy and safety of the VPZ-based therapy regimen in a larger population are warranted, particularly in other regions besides Japan. Future research should also focus on exploring the mechanism by which the VPZ-based therapy regimen remains unaffected by alcohol intake.

Strengths and limitations of analysis

The present study has several limitations. First, several confounding factors differed among studies, such as BMI, race, study design, and treatment regimen; this may have influenced the results of our study. Second, studies have shown that the existence of the dose–response gradient can improve the quality of evidence [54]. Since only seven Asian studies provided information on alcohol intake, the questionnaire was not an ideal source of data in most Asian studies included herein. Therefore, we could only incorporate these seven studies into the dose–response analysis of alcohol consumption and H. pylori eradication. Further studies are needed to examine the relationship between different alcohol intake doses and the corresponding risk of H. pylori eradication failure. Third, we did not analyze the effect of the type of alcohol consumed on H. pylori eradication rates, and since different types of alcohol have different potentially relevant properties in this regard, for example, some studies have shown that wine has antibacterial properties, this perspective deserves further exploration [55, 56]. Finally, most of the included studies did not test for antibiotic resistance in their trials, which may have influenced the H. pylori eradication rate. Nonetheless, despite these limitations, to our knowledge, this is the first meta-analysis to explore the relationship between alcohol consumption and the risk of H. pylori eradication failure. In addition, VPZ is a novel P-CAB that has been recently approved in Japan for H. pylori eradication. We included relevant literature to provide the first comprehensive analysis of whether alcohol consumption has an effect on H. pylori eradication in individuals undergoing the VPZ-based therapy. Further large-scale, multicenter prospective studies are warranted to verify our results.

Conclusion

In summary, our meta-analysis suggests that alcohol consumption increases the H. pylori eradication failure rate in Asian populations. Alcohol intake of > 40 g/day was associated with H. pylori eradication failure. It should also be noted that alcohol consumption may not negatively affect H. pylori eradication rates when the VPZ-based therapy regimen is being used to treat H. pylori infection in Asian populations. Therefore, we suggest that for Asian populations, drinkers should abstain from alcohol to improve the H. pylori eradication rate; furthermore, in patients having difficulty in abstaining from alcohol, the VPZ-based therapy regimen can be adopted to avoid the influence of alcohol on treatment efficacy.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter. 2019;24: e12591.

    PubMed  Google Scholar 

  2. Takara Y, Endo H, Nakano R, et al. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin. Digestion. 2019;99:172–8.

    PubMed  CAS  Google Scholar 

  3. Eto H, Suzuki S, Kusano C, et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26: e12788.

    PubMed  CAS  Google Scholar 

  4. Malfertheiner P, Megraud F, O’Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.

    PubMed  CAS  Google Scholar 

  5. Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol. 2019;25:1907–12.

    PubMed  PubMed Central  CAS  Google Scholar 

  6. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160:1831–41.

    PubMed  Google Scholar 

  7. Yao CC, Kuo CM, Hsu CN, et al. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist. 2019;29:1425–31.

    Google Scholar 

  8. Manes G, Pieramico O, Perri F, et al. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci. 2005;50:443–8.

    PubMed  CAS  Google Scholar 

  9. Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022;27:e12860.

    PubMed  CAS  Google Scholar 

  10. Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005;3:564–73.

    PubMed  CAS  Google Scholar 

  11. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9–18.

    PubMed  CAS  Google Scholar 

  12. Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24:4596–605.

    PubMed  PubMed Central  Google Scholar 

  13. Yi DM, Yang TT, Chao SH, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore). 2019;98: e14408.

    PubMed  CAS  Google Scholar 

  14. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993;88:505–9.

    PubMed  CAS  Google Scholar 

  15. Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo. 2001;56:11–6.

    PubMed  CAS  Google Scholar 

  16. Okubo H, Akiyama J, Kobayakawa M, et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol. 2020;55:1054–61.

    PubMed  CAS  Google Scholar 

  17. Noda H, Noguchi S, Yoshimine T, et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25:283–8.

    PubMed  Google Scholar 

  18. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    PubMed  PubMed Central  Google Scholar 

  19. Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994;29:1070–5.

    PubMed  CAS  Google Scholar 

  20. Hazell SL, Daskalopoulous G, Mitchell HM, Massey D. Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 1997;12:93–9.

    PubMed  CAS  Google Scholar 

  21. Olafsson S, Berstad A, Bang CJ, et al. Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Aliment Pharmacol Ther. 1999;13:651–9.

    PubMed  CAS  Google Scholar 

  22. Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter. 1999;4:204–10.

    PubMed  CAS  Google Scholar 

  23. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000;95:914–20.

    PubMed  CAS  Google Scholar 

  24. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard “Maastricht triple therapy.” Aliment Pharmacol Ther. 2001;15:1023–9.

    PubMed  CAS  Google Scholar 

  25. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi PG. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol. 2001;96:359–66.

    PubMed  CAS  Google Scholar 

  26. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol. 2002;14:1237–43.

    PubMed  CAS  Google Scholar 

  27. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol. 2002;35:315–20.

    PubMed  CAS  Google Scholar 

  28. Baena JM, López C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol. 2002;14:291–6.

    PubMed  CAS  Google Scholar 

  29. Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy–results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17:99–109.

    PubMed  CAS  Google Scholar 

  30. Ishioka H, Mizuno M, Take S, et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion. 2007;75:63–8.

    PubMed  CAS  Google Scholar 

  31. Namiot DB, Leszczyńska K, Namiot Z, Kurylonek AJ, Kemona A. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci. 2008;53:310–5.

    PubMed  CAS  Google Scholar 

  32. Singh N, Deb R, Kashyap PC, Bhatia V, Ahuja V, Sharma MP. Body mass index and per capita income influence duodenal ulcer healing and H. pylori eradication whilst dietary factors play no part. Trop Gastroenterol. 2008;29:26–31.

    PubMed  Google Scholar 

  33. Gatta L, Di Mario F, Vaira D, et al. Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med. 2011;6:35–9.

    PubMed  Google Scholar 

  34. Lim JH, Lee DH, Lee ST, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol. 2015;21:13124–31.

    PubMed  PubMed Central  CAS  Google Scholar 

  35. Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801–7.

    PubMed  PubMed Central  Google Scholar 

  36. Tsai CE, Liang CM, Lee CH, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32:397–402.

    PubMed  Google Scholar 

  37. Huh CW, Youn YH, da Jung H, Park JJ, Kim JH, Park H. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. PLoS ONE. 2016;11:e0162258.

    PubMed  PubMed Central  Google Scholar 

  38. Ahn HJ, Kim DP, Chu MS, et al. Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections. Gastroenterol Res Pract. 2017;2017:1654907.

    PubMed  PubMed Central  Google Scholar 

  39. Chang YW, Ko WJ, Oh CH, et al. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med. 2019;34:1022–9.

    PubMed  CAS  Google Scholar 

  40. Jin Y, Zhang S, Pan J, et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis. Pharmazie. 2019;74:432–8.

    PubMed  CAS  Google Scholar 

  41. Ozeki K, Asano M, Furuta T, Ojima T. Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic. Epidemiol Infect. 2019;147: e292.

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med. 2021;22:547–56.

    PubMed  CAS  Google Scholar 

  43. Lin CK, Hsu PI, Lai KH, et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol. 2002;34:547–51.

    PubMed  Google Scholar 

  44. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005;100:2387–92.

    PubMed  CAS  Google Scholar 

  45. Lee JY, Kim N, Kim MS, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235–43.

    PubMed  CAS  Google Scholar 

  46. Kasai T, Suzuki S, Kusano C, et al. High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection. Tohoku J Exp Med. 2021;253:85–94.

    PubMed  CAS  Google Scholar 

  47. Morasso MI, Hip A, Márquez M, González C, Arancibia A. Amoxicillin kinetics and ethanol ingestion. Int J Clin Pharmacol Ther Toxicol. 1988;26:428–31.

    PubMed  CAS  Google Scholar 

  48. Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. J Pharm Pharmacol. 2013;65:1518–25.

    PubMed  CAS  Google Scholar 

  49. Takeuchi F, Isono M, Nabika T, et al. Confirmation of ALDH2 as a Major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. Circ J. 2011;75:911–8.

    PubMed  CAS  Google Scholar 

  50. Goedde HW, Agarwal DP, Harada S, et al. Population genetic studies on aldehyde dehydrogenase isozyme deficiency and alcohol sensitivity. Am J Hum Genet. 1983;35:769–72.

    PubMed  PubMed Central  CAS  Google Scholar 

  51. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.

    PubMed  CAS  Google Scholar 

  52. Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16:667–85.

    PubMed  PubMed Central  Google Scholar 

  53. Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019;24:e12597.

    PubMed  Google Scholar 

  54. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.

    PubMed  PubMed Central  Google Scholar 

  55. Weisse ME, Eberly B, Person DA. Wine as a digestive aid: comparative antimicrobial effects of bismuth salicylate and red and white wine. BMJ. 1995;311:1657–60.

    PubMed  PubMed Central  CAS  Google Scholar 

  56. Marimón JM, Bujanda L, Gutiérrez-Stampa MA, Cosme A, Arenas JI. In vitro bactericidal effect of wine against Helicobacter pylori. Am J Gastroenterol. 1998;93:1392.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank all our authors listed in this manuscript.

Funding

This work was supported by the Changzhou special fund for introducing foreign talents (CQ20204037), the Jiangsu postdoctoral fund (2020Z182), and the Changzhou High-Level Medical Talents Training Project (2022CZBJ051).

Author information

Author notes

  1. Jing Yu and Yiming Lv should be considered joint first author.

Authors and Affiliations

  1. Department of Gastroenterology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, 29 Xinglong Lane, Tianning District, Changzhou, 213000, Jiangsu Province, China

    Jing Yu, Yiming Lv, Peng Yang, Yizhou Jiang, Xiangrong Qin & Xiaoyong Wang

  2. Graduate School, Dalian Medical University, 9 West Section of Lushun South Road, Lvshunkou District, Dalian, 116000, Liaoning Province, China

    Jing Yu & Peng Yang

Authors
  1. Jing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yiming Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yizhou Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiangrong Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaoyong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Xiaoyong Wang: conception and design of the study, critical revision, acquisition of data, analysis and interpretation of data, drafting the article, final approval; Xiangrong Qin: conception and design of the study, critical revision, acquisition of data, analysis and interpretation of data, final approval; Jing Yu, Yiming Lv: acquisition of data, analysis and interpretation of data, drafting the article, final approval; Peng Yang, Yizhou Jiang: interpretation of data, revising the article, final approval.

Corresponding author

Correspondence to Xiaoyong Wang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, J., Lv, Y., Yang, P. et al. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations. BMC Gastroenterol 23, 365 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s12876-023-03002-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12876-023-03002-z

Keywords

BMC Gastroenterology

ISSN: 1471-230X

Contact us